Decreased VLDL-Apo B 100 fractional synthesis rate despite hypertriglyceridemia in subjects with type 2 diabetes and nephropathy
| Autor: | Michela Zanetti, Gloria Pasqualetto, Monica Vettore, Lucia Puricelli, Edward Kiwanuka, Gianna Toffolo, Carlo Gabelli, Rocco Barazzoni, I. Cortella, Erica Manesso, Paolo Tessari |
|---|---|
| Přispěvatelé: | Tessari, Paolo, Kiwanuka, Edward, Barazzoni, Rocco, Toffolo, Gianna M, Vettore, Monica, Cortella, Irene, Manesso, Erica, Pasqualetto, Gloria, Puricelli, Lucia, Gabelli, Carlo, Zanetti, Michela |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Blood Glucose
Male Very low-density lipoprotein Apolipoprotein B Endocrinology Diabetes and Metabolism Clinical Biochemistry Type 2 diabetes Lipoproteins VLDL Biochemistry Diabetic nephropathy Endocrinology VLDL-Apo B 100 Insulin Medicine Diabetic Nephropathies Hypertriglyceridemia biology Middle Aged Diabetes and Metabolism Apolipoprotein B-100 Female lipids (amino acids peptides and proteins) VLDL Type 2 Adult medicine.medical_specialty Lipoproteins Aged Diabetes Mellitus Type 2 Humans Kinetics Leucine Radiopharmaceuticals Biochemistry (medical) T2DM Context (language use) VLDL-Apo B 100 T2DM Nephropathy Internal medicine Diabetes Mellitus Radionuclide Imaging business.industry nutritional and metabolic diseases medicine.disease biology.protein business Lipoprotein |
| DOI: | 10.1210/jc.2015-2172 |
| Popis: | Subjects with type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN) often exhibit hypertriglyceridemia. The mechanism(s) of such an increase are poorly known.We investigated very low-density lipoprotein (VLDL)-Apo B 100 kinetics in T2DM subjects with and without DN, and in healthy controls.Stable isotope (13)C-leucine infusion and modeling analysis of tracer-to-tracee ratio dynamics in the protein product pool in the 6-8-h period following tracer infusion were employed.Male subjects affected by T2DM, either with (n = 9) or without (n = 5) DN, and healthy male controls (n = 6), were studied under spontaneous glycemic levels in the post-absorptive state.In the T2DM patients with DN, plasma triglyceride (TG) (mean ± SD; 2.2 ± 0.8 mmol/L) and VLDL-Apo B 100 (17.4 ± 10.4 mg/dL) concentrations, and VLDL-Apo B 100 pool (0.56 ± 0.29 g), were ∼60-80% greater (P.05 or less) than those of the T2DM subjects without DN (TG, 1.4 ± 0.5 mmol/L; VLDL-Apo B 100, 9.9 ± 2.5 mg/dL; VLDL-Apo B 100 pool, 0.36 ± 0.09 g), and ∼80-110% greater (P.04 or less) than those of nondiabetic controls (TG, 1.2 ± 0.4 mmol/L; VLDL-Apo B 100, 8.2 ± 1.7 mg/dL; VLDL-Apo B 100, 0.32 ± 0.09 g). In sharp contrast however, in the subjects with T2DM and DN, VLDL-Apo B 100 fractional synthesis rate was ≥50% lower (4.8 ± 2.2 pools/d) than that of either the T2DM subjects without DN (9.9 ± 4.3 pools/d; P.025) or the control subjects (12.5 ± 9.1 pools/d; P.04).The hypertriglyceridemia of T2DM patients with DN is not due to hepatic VLDL-Apo B 100 overproduction, which is decreased, but it should be attributed to decreased apolipoprotein removal. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|